Pain Management Review and Outlook 2011
UBM Canon, February 2011, Pages: 68
Industry analysts estimate that more than 1.5 billion people around the world suffer from chronic pain, making it the number one reason patients seek medical care. In fact, studies have shown that pain leads to more than 50 million lost workdays each year. The cost of pain, including medical bills and lost workdays, is estimated at $100 billion per year. The U.S. market for pain-management therapeutics is estimated to generate more than $40 billion and is predicted to grow to $60 billion by 2015. This market includes treatments for a wide range of conditions including postoperative pain, cancer pain, arthritis pain, migraine pain, neuropathic pain, and back pain.
This medical segment consists of products such as opioids, nonsteroidal anti-inflammatory drugs, acetaminophen, local anesthetics, tricyclic antidepressants, anticonvulsants, patient-controlled dosing, implants, and electrical stimulation. Many pain medications, while effective, cause unwanted side effects. Opioids, the largest pain-therapy class, are widely known to cause a number of side effects such as nausea, vomiting, constipation, and somnolence. They can also cause severe respiratory depression. Nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to cause gastrointestinal upset, kidney and liver damage, and they can increase cardiovascular risks. A higher demand for more efficient drugs, delivery systems, and medical devices for pain treatment is driving the pain-management market.
The need to address acute and chronic pain will rise alongside an increasingly aging population. Other factors affecting the future of the pain-management segment include a growing number of surgical procedures being performed, changing lifestyles, and increasing incidences of cancer. Providing solutions for pain prevention and treatment continues to garner the attention of R&D managers and other industry executives. Accordingly, potential new blockbuster drugs are expected to penetrate the market including Remoxy, an oxycodone drug that is meant to be more abuse-resistant than OxyContin.
This special report focuses on the market leaders for pain management as well as the products in development anticipated to head this area in the years to come. This compilation’s prescription-product pipeline details the following information for each medicine: chemical or substance composition, intended indication, class of drug, clinical status, region of development, and the product developer/intended marketer. Pipeline status details preclinical development, Phase I, Phase I/II, Phase II, Phase II/III, Phase III, and awaiting approval. Regions of development include the United States, Europe, and Japan. A directory of pain management prescription-drug developers and marketers is included.
Additionally provided in this report is a listing of pain management medical-device entries, sorted by device class, as well as a directory of medical-device companies associated with the pain management field.
Pain-Management Market Overview
Pain-Management Company Review
Pain-Management Prescription Drug and Biologic Pipeline
Awaiting Approval
Phase III
Phase II/III
Phase II
Phase I/II
Phase I
Preclinical
Prescription Pain-Management Developers and Marketers
Pain-Management Devices
Class I
Class II
Class III
Pain-Management Medical-Device Developers and Marketers
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
